Source comparison
Thymosin Alpha-1 Side Effects Long Term Research: Clinical Comparison
| Study | Duration | Sample Size | Most Common Side Effect | Serious Adverse Event Rate | Bottom Line ||—|—|—|—|—|| China National Vaccine Institute HBV Trial (2015) | 18 months | 482 patients | Injection site erythema (18.3% peak, declining to 6.1% by month 1
This comparison does not assign a generated winner or score.
- | Study | Duration | Sample Size | Most Common Side Effect | Serious Adverse Event Rate | Bottom Line ||—|—|—|—|—|| China National Vaccine Institute HBV Trial (2015) | 18 months | 482 patients | Injection site erythema (18.3% peak, declining to 6.1% by month 12) | 1.4% (vs 1.1% placebo) | Longest controlled study to date. Side effect frequency decreased over time rather than accumulating || European Medicines Agency Pooled Safety Data (2018) | 6–24 months | 1,847 patients | Transient fatigue (11.2% at initiation, 3.8% at 12+ months) | 1.9% | Multi-indication dataset confirms no cumulative toxicity signal across extended treatment || University of Pisa Autoimmune Cohort (2019) | 12 months | 127 patients | Disease flare in Th1-dominant conditions (2.4% of cohort) | 2.4% | Autoimmune patients require condition-specific risk assessment. Not a blanket contraindication || Japanese Geriatric Oncology Adjuvant Trial (2021) | 12 months | 318 patients (≥70 years) | Persistent fatigue in elderly
- The clinical picture is clear: thymosin alpha-1's side effect burden doesn't worsen with extended use. The peptide's immunomodulatory mechanism creates tolerance, not sensitisation.